Enanta Pharmaceuticals Share Price (NASDAQ: ENTA)

$8.39

▲

-0.3

(-3.45%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Enanta Pharmaceuticals Stock chart to analyse performance

Enanta Pharmaceuticals stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$8.39
Today's High:$8.75
$8.39
0.0%
Downside
Day's Volatility :4.11%
Upside
4.11%
52 Weeks Low:$4.09
52 Weeks High:$13.37
$8.39
51.25%
Downside
52 Weeks Volatility :69.41%
Upside
37.25%

Enanta Pharmaceuticals Stock Returns

Period	Enanta Pharmaceuticals Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	33.86%	3.6%	0.0%
6 Months	14.87%	-7.7%	0.0%
1 Year	-33.28%	-12.6%	0.0%
3 Years	-86.96%	9.5%	-4.7%

Enanta Pharmaceuticals Inc Key Stats

Check Enanta Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$8.69
Open	$8.71
Today's High	$8.75
Today's Low	$8.39
Market Capitalization	$179.6M
Today's Volume	$75.9K
52 Week High	$13.3699
52 Week Low	$4.09
Revenue TTM	$64.8M
EBITDA	$-93.0M
Earnings Per Share (EPS)	$-4.32
Profit Margin	-141.98%
Quarterly Earnings Growth YOY	-0.66%
Return On Equity TTM	-80.64%

Stock Returns calculator for Enanta Pharmaceuticals Stock including INR - Dollar returns

The Enanta Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Enanta Pharmaceuticals investment value today

Current value as on today

₹70,424

Returns

₹29,576

(-29.58%)

Returns from Enanta Pharmaceuticals Stock

₹34,860 (-34.86%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Enanta Pharmaceuticals Stock

-25%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Enanta Pharmaceuticals Stock from India on INDmoney has decreased by -25% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Enanta Pharmaceuticals Inc

Name
Holdings %
Name
Holdings %
Farallon Capital Management, L.L.C.
9.93%
Krensavage Asset Management, LLC
9.89%
BlackRock Inc
9.44%
Vanguard Group Inc
9.25%
Millennium Management LLC
6.30%
Acadian Asset Management LLC
4.06%

Analyst Recommendation on Enanta Pharmaceuticals Stock

Rating

Trend

Buy

64%Buy

28%Hold

7%Sell

Based on 14 Wall street analysts offering stock ratings for Enanta Pharmaceuticals(by analysts ranked 0 to 5 stars)

Enanta Pharmaceuticals Share Price Target

What analysts predicted

Upside of 110.57%

Target:

$17.67

Current:

$8.39

Enanta Pharmaceuticals share price target is $17.67, a slight Upside of 110.57% compared to current price of $8.39 as per analysts' prediction.

Enanta Pharmaceuticals Stock Insights

Price Movement
In the last 3 years, ENTA stock has moved down by -85.9%
Increasing Revenue
Revenue is up for the last 2 quarters, 14.92M → 18.31M (in $), with an average increase of 18.5% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -22.64M → -18.25M (in $), with an average increase of 24.0% per quarter
ENTA vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 104.5%
ENTA vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 198.5%
Price to Sales
ForENTA every $1 of sales, investors are willing to pay $2.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Enanta Pharmaceuticals Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$205.2M	↓ 0.69%
Net Income	$46.4M	↓ 35.54%
Net Profit Margin	22.6%	↓ 12.22%

	FY20	Y/Y Change
Revenue	$122.5M	↓ 40.31%
Net Income	$-36.2M	↓ 177.98%
Net Profit Margin	-29.53%	↓ 52.13%

	FY21	Y/Y Change
Revenue	$97.1M	↓ 20.74%
Net Income	$-79.0M	↑ 118.41%
Net Profit Margin	-81.38%	↓ 51.85%

	FY22	Y/Y Change
Revenue	$86.2M	↓ 11.24%
Net Income	$-121.8M	↑ 54.13%
Net Profit Margin	-141.31%	↓ 59.93%

	FY23	Y/Y Change
Revenue	$79.2M	↓ 8.07%
Net Income	$-133.8M	↑ 9.91%
Net Profit Margin	-168.95%	↓ 27.64%

	FY24	Y/Y Change
Revenue	$67.6M	↓ 14.61%
Net Income	$-116.0M	↓ 13.28%
Net Profit Margin	-171.58%	↓ 2.63%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$17.1M	↓ 5.27%
Net Income	$-31.2M	↓ 6.74%
Net Profit Margin	-182.7%	↑ 2.86%

	Q2 FY24	Q/Q Change
Revenue	$18.0M	↑ 5.38%
Net Income	$-22.7M	↓ 27.28%
Net Profit Margin	-126.08%	↑ 56.62%

	Q3 FY24	Q/Q Change
Revenue	$14.6M	↓ 18.72%
Net Income	$-28.8M	↑ 27.21%
Net Profit Margin	-197.32%	↓ 71.24%

	Q4 FY24	Q/Q Change
Revenue	$17.0M	↑ 16.1%
Net Income	$-22.3M	↓ 22.67%
Net Profit Margin	-131.43%	↑ 65.89%

	Q1 FY25	Q/Q Change
Revenue	$14.9M	↓ 11.99%
Net Income	$-22.6M	↑ 1.59%
Net Profit Margin	-151.71%	↓ 20.28%

	Q2 FY25	Q/Q Change
Revenue	$18.3M	↑ 22.7%
Net Income	$-18.3M	↓ 19.38%
Net Profit Margin	-99.68%	↑ 52.03%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$205.2M	↓ 0.69%

	FY20	Y/Y Change
Profit	$122.5M	↓ 40.31%

	FY21	Y/Y Change
Profit	$97.1M	↓ 20.74%

	FY22	Y/Y Change
Profit	$86.2M	↓ 11.24%

	FY23	Y/Y Change
Profit	$79.2M	↓ 8.07%

	FY24	Y/Y Change
Profit	$67.6M	↓ 14.61%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$17.1M	↓ 5.27%

	Q2 FY24	Q/Q Change
Profit	$18.0M	↑ 5.38%

	Q3 FY24	Q/Q Change
Profit	$14.6M	↓ 18.72%

	Q4 FY24	Q/Q Change
Profit	$17.0M	↑ 16.1%

	Q1 FY25	Q/Q Change
Profit	$14.9M	↓ 11.99%

	Q2 FY25	Q/Q Change
Profit	$-31.9M	↓ 313.62%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$71.4M	↑ 144.41%
Investing Cash Flow	$-86.7M	↑ 144.8%
Financing Cash Flow	$2.6M	↓ 41.62%

	FY20	Y/Y Change
Operating Cash Flow	$7.1M	↓ 90.08%
Investing Cash Flow	$19.8M	↓ 122.88%
Financing Cash Flow	$9.0M	↑ 248.99%

	FY21	Y/Y Change
Operating Cash Flow	$-70.0M	↓ 1087.53%
Investing Cash Flow	$37.0M	↑ 86.54%
Financing Cash Flow	$3.1M	↓ 65.71%

	FY22	Y/Y Change
Operating Cash Flow	$-84.8M	↑ 21.12%
Investing Cash Flow	$54.9M	↑ 48.41%
Financing Cash Flow	$20.0M	↑ 550.42%

	FY23	Y/Y Change
Operating Cash Flow	$-103.2M	↑ 21.67%
Investing Cash Flow	$-53.6M	↓ 197.6%
Financing Cash Flow	$198.1M	↑ 889.0%

	FY24	Y/Y Change
Operating Cash Flow	$-78.8M	↓ 23.64%
Investing Cash Flow	$58.2M	↓ 208.69%
Financing Cash Flow	$-27.6M	↓ 113.94%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-28.6M	↑ 14.46%
Investing Cash Flow	$58.6M	↓ 546.93%
Financing Cash Flow	$-6.4M	↓ 12.73%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-14.8M	↓ 48.34%
Investing Cash Flow	$-6.3M	↓ 110.82%
Financing Cash Flow	$-6.6M	↑ 3.63%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-10.4M	↓ 29.61%
Investing Cash Flow	$19.1M	↓ 400.6%
Financing Cash Flow	$-7.2M	↑ 8.55%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-16.8M	↑ 61.55%
Investing Cash Flow	$68.9M	↑ 261.26%
Financing Cash Flow	$-5.0M	↓ 30.89%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-13.5M	↓ 19.72%
Investing Cash Flow	$-4.4M	↓ 106.34%
Financing Cash Flow	$-6.9M	↑ 38.13%

Enanta Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Enanta Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Enanta Pharmaceuticals Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Enanta Pharmaceuticals Inc	18.42%	14.87%	-33.28%	-86.96%	-83.1%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Enanta Pharmaceuticals Inc	NA	NA	0.0	-3.69	-0.81	-0.17	NA	3.71
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Enanta Pharmaceuticals Inc	Buy	$179.6M	-83.1%	NA	-141.98%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Organization	Enanta Pharmaceuticals
Employees	131
CEO	Dr. Jay R. Luly Ph.D.
Industry	Health Technology

Key Management of Enanta Pharmaceuticals Inc

Name	Title
Dr. Jay R. Luly Ph.D.	President, CEO & Director
Mr. Paul J. Mellett Jr.	Chief Financial & Administrative Officer
Dr. Yat Sun Or Ph.D.	Chief Scientific Officer
Mr. Matthew P. Kowalsky J.D.	Chief Legal Officer & Corporate Secretary
Dr. Scott T. Rottinghaus M.D.	Chief Medical Office
Ms. Jennifer Viera	Executive Director of Investor Relations & Corporate Communications
Mr. Nathaniel S. Gardiner J.D.	Consultant
Ms. Tara Lynn Kieffer Ph.D.	Chief Product Strategy Officer
Mr. Brendan Luu	Chief Business Officer

Important FAQs about investing in ENTA Stock from India :

What is Enanta Pharmaceuticals share price today?

Enanta Pharmaceuticals share price today is $8.39 as on August 30, 2025 at 1:29 am IST at the close of the market. Enanta Pharmaceuticals share today touched a day high of $8.75 and a low of $8.39.

What is the 52 week high and 52 week low for Enanta Pharmaceuticals share?

Enanta Pharmaceuticals share touched a 52 week high of $13.37 and a 52 week low of $4.09. Enanta Pharmaceuticals stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $8.39, lower by 37.25% versus the 52 week high.

How to invest in Enanta Pharmaceuticals Stock (ENTA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Enanta Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Enanta Pharmaceuticals Shares that will get you 0.1788 shares as per Enanta Pharmaceuticals share price of $8.39 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Enanta Pharmaceuticals Stock (ENTA) from India?

Indian investors can start investing in Enanta Pharmaceuticals (ENTA) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Enanta Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Enanta Pharmaceuticals share’s latest price of $8.39 as on August 30, 2025 at 1:29 am IST, you will get 1.1919 shares of Enanta Pharmaceuticals. Learn more about fractional shares .

What are the returns that Enanta Pharmaceuticals has given to Indian investors in the last 5 years?

Enanta Pharmaceuticals stock has given -83.1% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?